ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Matched conditions: ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Matched conditions: ER-POSITIVE HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC